Tryptamine Based Medication

Baileneu Ma produces a variety of tryptamine based medications for treatment of depression, OCD, PTSD, Bipolar Disorder, Addiction (mainly Alcoholism and Opiate Addiction), Glaucoma and cluster headaches. These drugs can be used in both therapy and on a prescription basis, with a variety of different TBs being used in conjunction with other medications, although care should be taken when combining TB antidepressants and MAOi/SSRI antidepressants in order to avoid. Tryptamine based medicines have been used in Baileneu Ma since the 1980s, but were largely unused in other nations until recent years, given the success of current 3rd gen TB antidepressants. There are currently three generations of TB antidepressants, 1st gen includes: Estranopryn and Indopryn; 2nd gen includes: Ginapryn and Deslopryn; 3rd gen includes: Effizapryn, Trandopryn and Meprosyn.

Estranopryn
Estranopryn (4-PO-Dimethyltryptamine) was the first tryptamine based medication that was licensed in 1986, being prescribed in 5mg doses once a day for treatment of depression and OCD, as well as administered in doses up to 20mg for use in therapy sessions, where it was deemed most effective. Doctors in Baileneu Ma reportedly prescribed Estranopryn in 83% of depression cases, with a double blind survey leading to 62% of participants having moderate relief from symptoms, whereas the placebo only only caused moderate relief in 21% of participants. Notable side-effects include nausea, hypotension, mydriasis and disorientation, in higher doses, side-effects include: hallucinations, euphoria, paranoia and in rarer cases, delirium and panic attacks.

Indopryn
Indopryn (Alpha-Methyltryptamine) was developed in 1988 as a more potent cousin of Estranopryn, with more stimulating and entheogenic effects making it more effective in therapy and on a prescription (5-10 mg doses). However, it was considerably more strong and there worries of neurotoxicity due it's similarities with Alpha-Ethyltryptamine, with side-effects including mydriasis, tachycardia, hallucinations, anxiety, trismus, headaches, nausea and vomiting. Because of this, Indopryn is typically reserved for atypical depression, where all other medications are unavailable or have been exhausted.

Ginapryn
Ginapryn (4-AcO-Dimethyltryptamine) was developed in 1995 as a way to reduce nausea, body load and other undesirable effects associated with Estranopryn, whilst still maintaining the anti-depressant effects. Ginapryn largely replaced Estranopryn in Bailenese medical practitioners, although in some rural areas it is reported that Estranopryn is still used as it can be produced without access to chemical processing equipment. Side-effects and medical effectiveness are largely similar to Estranopryn, due to both chemicals being very similar, however, Ginapryn is reportedly more hallucinogenic and shorter lasting. Ginapryn is typically issued in cases of PTSD or depression, where it is more effective than Estranopryn.

Deslopryn
Deslopryn (4-HO-Dimethyltryptamine) is an uncommon tryptamine based antidepressant that was only briefly used in 1998 for patients more susceptible to nausea associated with Ginapryn and Estranopryn. Whilst not truly removing the nauseating effects of dimethyltryptamine, it helped roughly 21% of patients prescribed a TB deal with nausea and other unpleasant side-effects to a greater extent to Ginapryn. Currenty Deslopryn in only used in hospitals under certain circumstances, where a person might be malnourished or dehydrated and in need of medication.

Meprosyn
Meprosyn (4-HO-5-MeO-Dimethyltryptamine) was developed in 2012 as an alternative to Indopryn that keeps the same potency, but has a better safety profile and can be used in smaller doses for a prescription anti-depressant and can be used in higher doses for psychotherapy. It is also incredibly easy to produce, where by placing the bark of a Virola tree in the substrate of psilocybes mushrooms, leading to an increase in popularity in rural areas where it can be produced in large quantities cheaply and efficiently.

Effizapryn
Effizapryn (1-Methyl-4-HO-Dimethyltryptamine) was developed in 2014 as a weaker anti-depressant used in treatment for OCD and depression, as well as glaucoma and cluster headaches. Effizapryn isn't psychoactive in high doses and removes many of the previous side effects such as hallucinations, delirium, panic attacks and dissociation. Effizapryn is currently being licensed in many other nations, such as Helinika and Zahava.

Trandopryn
Trandopryn (4-HO-Diethyltryptamine) was developed in 2012 as a treatment for Bipolar Disorder as a safer alternative to anti-psychotic agents and mood balancing drugs. It carries a very similar safety profile to existing TBs, making it far more preferable to existing treatments for BPD, although it can be used in conjunction to anti-psychotics such as Olanzopine and Risperidrone, as well as Lithium supplements. When treating BPD, high doses of TBs must never be used in order to avoid any psychotic episodes from mood altering side-effects such as panic attacks or delirium.

4th Generation
The next generation of TBs are currently being developed in Baileneu Ma and carry better safety profiles and stronger effects, currently being investigated is 5-MeO-Dimethyltryptamine, 4-HO-methyl-N-isopropyltryptamine and 5-MeO-methyl-N-isopropyltryptamine for prescription antidepressants and 4-HO-diisopropyltryptamine for use in psychotherapy.